Cholesterol screening programmes are unlikely to reduce mortality and can be misleading or harmful.
Blood cholesterol used as a measure on its own is a poor predictor of risk from CHD.
Cholesterol is only one factor in CHD which must be considered alongside other modifiable risk factors.
Cholesterol lowering with statins should be targeted at those at high risk of CHD events.
Some other drug treatments and lifestyle changes are more cost-effective than the use of statins.
Priority should be given to the appropriate use of the most cost-effective interventions in both primary and secondary care settings.